TICKERNERD
Menu
ATYRATYRHealthcare · Biotechnology

ATYR Stock Forecast: aTyr Pharma, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$0.28
−1.66% on the day

The 9 Wall Street analysts covering aTyr Pharma, Inc. hold a median 12-month price target of $3 — +978.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 6 Oct 2026 — in the upper half.

Market cap
$27.8M
Ticker Nerd rank
53 / 100
Median analyst target
$3.00
Analysts covering
9
Revenue$0.0
Operating income−$10.9M
Net income−$10.3M
Free cash flow−$9.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.2%
1M
−44.0%
YTD
−64.5%
1Y
−66.7%
From 52W high
−73.7%
From 52W low
0.0%
$0.28
$1.06
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ATYR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores aTyr Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Growth
83
Accruals
77
Revisions
70
Volatility
60
Issuance
59
Quality
30
Value
7
Momentum
2

Size (86): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ATYR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATYR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26ATYRHigh $7.00Median $3.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
4 Buy5 Hold0 Sell
Low $1.00Median $3.00High $7.00

The green dot is the last close — the median target sits +978.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 May 2026Freedom BrokerUpgradeBuy$1.00 → $3.50
7 Nov 2025RBC CapitalMaintainsSector Perform—
16 Sept 2025RBC CapitalDowngradeSector Perform—
16 Sept 2025Wells FargoDowngradeEqual-Weight—
15 Sept 2025Cantor FitzgeraldDowngradeNeutral—
15 Sept 2025HC Wainwright & Co.DowngradeNeutral—
15 Sept 2025Jones TradingDowngradeHold—
15 Sept 2025Leerink PartnersDowngradeMarket Perform—
15 Sept 2025LUCID CAPITAL MARKETSDowngradeNeutral—
22 Aug 2025JefferiesMaintainsBuy—
20 June 2025Wells FargoMaintainsOverweight—
4 June 2025HC Wainwright & Co.ReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
14 Mar 2025HC Wainwright & Co.ReiteratesBuy—
18 Feb 2025Leerink PartnersInitiatesOutperform—
6 Jan 2025Cantor FitzgeraldInitiatesOverweight—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
3 Dec 2024HC Wainwright & Co.ReiteratesBuy—
29 Oct 2024HC Wainwright & Co.ReiteratesBuy—
4 Oct 2024Wells FargoInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATYR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ATYR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, aTyr Pharma, Inc. returned −66.7% against +17.4% for the S&P 500, dividends included.

ATYR vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26ATYRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ATYR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

aTyr Pharma, Inc. (ATYR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 79% of US stocks

Price / sales
147.7×

Cheaper than 3% of US stocks

Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
0.3×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−33609.5%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−98.7%

Higher than 14% of US stocks

Return on assets
−46.6%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

aTyr Pharma, Inc. (ATYR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • aTyr Pharma, Inc. has a market value of $27.8M and an enterprise value of −$18.5M.

  • Revenue in the twelve months to 30 June 2026: $190K.

  • Net income over the same four quarters: −$60.8M, a −32006.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.62.

  • Free cash flow in the twelve months to 30 June 2026: −$54.8M.

  • Shares outstanding: 98.1M.

  • Trailing P/E: −0.4×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • aTyr Pharma, Inc. employs 58 people — $3K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

ATYR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATYRaTyr Pharma, Inc.$27.8M
53
MCRBSeres Therapeutics, Inc.$27.8M
56
BYSIBeyondSpring, Inc.$28.5M
19
IGCIGC Pharma, Inc.$28.9M
6
QNCXQuince Therapeutics, Inc.$26.2M
31
GRDXGridAI Technologies Corp.$29.5M
19
CNTXContext Therapeutics, Inc.$29.6M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own aTyr Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATYR news & analysis

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease

Benzinga · 24 Sept 2026positive

aTyr Pharma announced it secured a formal agreement with the U.S. Food and Drug Administration regarding the Phase 3 study protocol for its lead therapeutic candidate, efzofitimod, for a rare lung disease. This FDA alignment pertains to the company's investigational drug development program.

Why it matters — A formal FDA agreement on the Phase 3 protocol is a key regulatory milestone for aTyr's lead candidate, efzofitimod, and its rare lung disease program.

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

GlobeNewsWire · 24 Sept 2026positive

aTyr Pharma announced alignment with the FDA on its global Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease, using forced vital capacity (FVC) as the primary endpoint. The company expects to initiate study-related activities in the fourth quarter of 2026.

Why it matters — This regulatory alignment advances aTyr's late-stage development program for efzofitimod, an important step for its pulmonary sarcoidosis pipeline.

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

GlobeNewsWire · 1 Sept 2026neutral

aTyr Pharma provided an update on the expected timing of a response from the U.S. FDA regarding the protocol it submitted in June 2026 for a planned Phase 3 study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The company is a clinical-stage biotechnology firm developing first-in-class medicines from its tRNA synthetase platform.

Why it matters — ATYR watchers would care because this FDA response timing affects the advancement of efzofitimod's planned Phase 3 program in pulmonary sarcoidosis.

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

GlobeNewsWire · 7 Aug 2026neutral

aTyr Pharma announced its second quarter 2026 results along with a program prioritization and corporate restructuring that includes a workforce reduction of approximately 60% to conserve capital and focus resources on its efzofitimod program in interstitial lung disease (ILD). The company is awaiting FDA comments by the end of August 2026 on a protocol submitted for a planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Why it matters — ATYR watchers would care because the company is concentrating its resources on the efzofitimod ILD program and awaiting FDA feedback on the planned Phase 3 sarcoidosis study, which represents a key next step for the pipeline.

FAQ

Frequently asked questions about ATYR stock

What is the ATYR stock price forecast for 2026-2027?

The 9 Wall Street analysts covering aTyr Pharma, Inc. have a median 12-month price target of $3, with estimates ranging from $1 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATYR stock a buy right now?

Of the 9 analysts covering aTyr Pharma, Inc., 4 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks aTyr Pharma, Inc. 53 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATYR?

As at 6 Oct 2026, aTyr Pharma, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

Will ATYR stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +978.0% from the last close, and Ticker Nerd's factor model ranks aTyr Pharma, Inc. 53 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATYR stock forecast for 2030?

No analyst covering aTyr Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATYR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $7 over the next 12 months.

How has ATYR stock performed over the past year?

aTyr Pharma, Inc. returned -66.7% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does aTyr Pharma, Inc. do?

aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines based on tRNA synthetase biology.

What is the latest news on ATYR?

The most recent item we track (Benzinga, 24 Sept 2026): "Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease". aTyr Pharma announced it secured a formal agreement with the U.S. Food and Drug Administration regarding the Phase 3 study protocol for its lead therapeutic candidate, efzofitimod, for a rare lung disease. This FDA alignment pertains to the company's investigational drug development program.

Company

About aTyr Pharma, Inc.

aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines based on tRNA synthetase biology. The company’s current work centers on efzofitimod, a selective NRP2 modulator being studied for interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-related ILD. aTyr Pharma also advances preclinical programs such as ATYR0101 for fibrosis and ATYR0750 for liver disorders, reflecting a pipeline aimed at inflammation, immune regulation, and tissue remodeling. Headquartered in San Diego, California, and founded in 2005, aTyr Pharma operates as a research-driven biopharmaceutical company with a focus on translating proprietary biology into potential therapeutic candidates for serious fibrotic and inflammatory conditions.

CEO Dr. Sanjay S. Shukla M.D., M.S. · 58 employees · United States · https://atyrpharma.com